Last reviewed · How we verify
STA-1
At a glance
| Generic name | STA-1 |
|---|---|
| Sponsor | Sinphar Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of STA-1 as an Add-on Treatment to Donepezil (PHASE2)
- Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STA-1 CI brief — competitive landscape report
- STA-1 updates RSS · CI watch RSS
- Sinphar Pharmaceutical Co., Ltd portfolio CI